Mechanism & Pharmacology of Chlordehydromethyltestosterone
Chlordehydromethyltestosterone is a 17-alpha-alkylated oral anabolic-androgenic steroid derived from testosterone by the addition of a 4-chloro group and a methyl group at the 17-beta position, originally synthesised in East Germany in the early 1960s. Structurally, it is best understood as a chlorinated derivative of Dehydromethyltestosterone (methandienone), with the 4-chloro substitution fundamentally altering its biological behaviour. That single halogen modification eliminates the compound's ability to convert via aromatase into oestrogen, meaning chlordehydromethyltestosterone does not aromatise under physiological conditions. This absence of oestrogenic conversion is one of its most pharmacologically significant characteristics, distinguishing it sharply from its structural cousin methandienone.
The compound binds the androgen receptor with moderate affinity — its anabolic-to-androgenic ratio is commonly cited at approximately 100:50 relative to testosterone (set at 100:100), indicating that anabolic signalling is retained while androgenic potency is substantially reduced. Chlordehydromethyltestosterone also binds sex hormone-binding globulin (SHBG) with notably high affinity, a property that has historically been studied as a mechanism for displacing other androgens from SHBG and thereby increasing their free concentration in plasma. This SHBG-binding characteristic adds a nuanced pharmacodynamic dimension to its use alongside other compounds.
Oral bioavailability is estimated between 70% and 85%, supported by the 17-alpha-alkylation that resists first-pass hepatic metabolism. The elimination half-life is approximately 16 hours, making once- or twice-daily dosing pharmacologically rational. Despite 17-alkylation conferring hepatotoxicity risk common to this drug class, the compound is generally considered less hepatotoxic at moderate doses than methandienone, though liver enzyme monitoring remains advisable during any oral androgen cycle. Urinary detection windows extend to approximately 40–50 days for the primary metabolite, a figure that has historically made it relevant in discussions around anti-doping testing timelines.
Application Context & User Groups
Chlordehydromethyltestosterone occupies a specific niche in performance physique development: it produces slow, steady, quality muscle accumulation rather than the rapid, oedema-associated size associated with wetter androgens. Athletes seeking to maintain weight-class eligibility, improve relative strength, or construct lean mass without significant water retention have historically favoured it for these reasons. The compound is particularly valued during caloric restriction phases where preserving nitrogen retention and muscle protein synthesis is paramount, and also during lean mass-building blocks where aesthetic quality of gains outweighs raw volume.
User profiles broadly fall into two categories. Intermediate and advanced resistance-trained individuals use the 20mg tablet tier to maximise daily anabolic stimulus while remaining within a range typically associated with manageable side-effect profiles. Entry-level users or those running shorter cycles — often 6 to 8 weeks — frequently begin at the 10mg concentration, allowing gradual titration. Female athletes in strength and physique sports have historically used very low doses due to the compound's comparatively mild androgenic index, though individual virilisation sensitivity varies considerably and should not be understated.
Cycle lengths typically range from 6 to 10 weeks. Because the compound does not aromatise, ancillary oestrogen management is usually unnecessary, which simplifies cycle architecture and reduces the number of concurrent compounds required. Its pronounced SHBG-binding affinity means it is commonly used as a lead-in compound at the start of a cycle — chlordehydromethyltestosterone displaces bound testosterone from SHBG, transiently elevating free testosterone before longer-acting injectable esters reach peak plasma levels. Strength athletes in combat sports, track and field, and powerlifting have all documented historical use, most infamously through the state-sponsored East German doping programme of the 1970s and 1980s, where it was administered under the codename "Oral Turinabol" to hundreds of athletes across multiple Olympic cycles.
Post-cycle therapy protocols following chlordehydromethyltestosterone-only cycles are conventional, involving SERM-based hypothalamic-pituitary-gonadal axis restoration, since the compound suppresses endogenous testosterone production through negative feedback — though the degree of suppression is generally reported as less severe than with highly androgenic or oestrogenic agents.
Range & Selection by Concentration and Pack Size
Our chlordehydromethyltestosterone category currently lists 22 products from 22 individual manufacturers, spanning two concentration tiers — 10mg per tablet and 20mg per tablet — and three pack configurations: 50 tablets, 100 tablets, and 105 tablets.
10mg per tablet — Entry and Precision Dosing Tier
The 10mg concentration is the most widely available and versatile option in this category, offering granular control over daily intake. This tier suits users new to the compound, those running shorter cycle lengths of 6–8 weeks, and advanced users who prefer splitting their daily dose across two administrations for steadier plasma levels. Apto-Turinabol 10mg by Beligas Pharmaceuticals in a 50-tablet pack is a concise, lower-commitment entry point — ideal for first-cycle experimentation or as a top-up pack. Turinadyn 10mg by Driada Medical and Turinabol 10mg by Hilma Biocare, both available in 100-tablet packs, are better suited to full 8–10 week runs where consistent daily dosing at 20–30mg (split across two or three 10mg tablets) is the goal. Turinabol Tablets 10mg by Genesis in a 50-tablet pack similarly suits a shorter 5–6 week bridge cycle. The 10mg tier also allows experienced users to dial in dosing alongside other anabolic compounds with maximum flexibility, adjusting by single-tablet increments.
20mg per tablet — Efficiency and Advanced Dosing Tier
The 20mg concentration reduces daily tablet count and suits intermediate to advanced users who have established their individual response at 10mg and are working toward daily doses in the 40–60mg range. Turanabol 20mg by Dragon-Pharma in a 100-tablet pack — representing 2,000mg of total active compound — provides sufficient volume for a full 8-week cycle at 40mg daily with tablets remaining for dose adjustment. The 20mg tier is best suited to users comfortable with the compound's effects and who require the efficiency of fewer tablets per dose rather than fine-grained titration. Pack sizes of 100 tablets at this concentration represent the most economical choice per milligram for longer cycles.
When selecting between manufacturers at the same concentration, factors such as tablet excipient quality, third-party batch verification, and manufacturer reputation within the community are relevant differentiators — all 22 brands stocked here are sourced from established pharmaceutical-grade underground laboratory operations with documented product histories.
Frequently Asked Questions
What is the difference between chlordehydromethyltestosterone and methandienone?
Chlordehydromethyltestosterone has a 4-chloro group that prevents aromatisation to oestrogen, whereas methandienone converts readily to oestrogen, causing water retention. As a result, chlordehydromethyltestosterone produces leaner, drier muscle gains with a lower androgenic profile, making it a distinct compound despite their shared structural ancestry.
Is a 10mg or 20mg tablet concentration better for a first cycle?
The 10mg concentration is generally preferable for a first cycle because it allows dose titration in small increments — starting at 20–30mg daily and adjusting based on individual response. The 20mg tablet is more efficient for experienced users who have confirmed their effective daily dose and prioritise convenience over dosing flexibility.
How long does chlordehydromethyltestosterone remain detectable?
The primary urinary metabolite of chlordehydromethyltestosterone can be detected for approximately 40 to 50 days following the last dose using standard immunoassay and confirmatory mass spectrometry methods. This extended detection window, relative to its 16-hour half-life, is due to metabolite persistence and remains relevant for anyone subject to anti-doping testing protocols.
Trusted Brand
